EGFR and glioblastoma: Erlotinib and gefitinib, first-generation EGFR inhibitors, despite having shown interesting data in the preclinical setting [70], did not then lead to an improvement in the outcome and response parameters in the treatment of patients with GBM, both as first-line treatment and at relapse [71,72,73,74,75].